Patent ID: 9192648
Filing Date: 2015-11-24
Classification: A61K,A61P

Abstract:
1. A method of treating myasthenia gravis comprising administering subcutaneously to a human subject in need thereof a therapeutically effective amount of an agent that binds complement C5 protein, wherein the agent is: (a) a protein comprising or consisting of the amino acid sequence of SEQ ID NO: 2; (b) a protein comprising or consisting of amino acids 19 to 168 of SEQ ID NO: 2; (c) a protein comprising or consisting of an amino acid sequence having at least 95% sequence identity to amino acids 19 to 168 of SEQ ID NO: 2; or (d) a fragment of SEQ ID NO: 2, wherein said fragment comprises six cysteine residues that are spaced relative to each other at a distance of 32 amino acids apart, 62 amino acids apart, 28 amino acids apart, 1 amino acid apart, and 21 amino acids apart, respectively, as arranged from the amino terminus to the carboxyl terminus of SEQ ID NO: 2, wherein said fragment inhibits cleavage of C5 by classical and alternative C5 convertases.